Table 3 Compliance to the National TB management guideline
Variables | Total | JDWNRH | PGH |
|---|---|---|---|
n (%) | n (%) | n (%) | |
Standard treatment regimen | |||
New Cases- 6 month rifampicin (2HRZE+4HR) | 105 (75.5) | 85 (76.5) | 20 (71.4) |
Retreatment cases- 8 month rifampicin (3HRZE+5HRE) | 10 (7.1) | 9 (8.1) | 1 (3.57) |
Modified- 9 to 12 months | 11 (7.9) | 11 (9.9) | 0 |
MDR Treatment- 18 to 20 months | 13 (9.3) | 6 (5.4) | 7 (25) |
Frequency | |||
Daily | 139 (100) | 111 (100) | 28 (100) |
Three times a week | 0 | 0 | 0 |
Dosage as per body weight | |||
Correct dosage | (100) | (100) | (100) |
Incorrect dosage | 0 | 0 | 0 |
Directly observed treatment | |||
Yes | 106 (76.2) | 82 (73.8) | 24 (85.7) |
No | 23 (16.5) | 22 (19.8) | 1 (3.5) |
Sometimes | 10 (7.1) | 7 (6.3) | 3 (10.7) |
DOT intensive phase | |||
Health staff | 86 (61.9) | 65 (58.5) | 21 (75.0) |
Family member | 35 (25.1) | 30 (27.0) | 5 (17.8) |
None | 18 (12.9) | 16 (14.4) | 2 (7.1) |
DOT continuation phase | |||
Health staff | 8 (5.7) | 3 (2.7) | 5 (17.8) |
Family member | 68 (48.9) | 51 (45.9) | 17 (60.7) |
None | 63 (45.3) | 57 (51.3) | 6 (21.4) |